Drug Discovery
By
Could Roche’s New Vabysmo Data Redefine Long-Term Care in “wet” age-related macular degeneration (nAMD)?
Key Highlights Durability Demonstrated in AVONELLE-XRoche presented four-year data from AVONELLE-X at the Euretina 2025 Congress, showing that…
Could Lilly’s Olomorasib Breakthrough Designation Reshape the First-Line Treatment Landscape in KRAS G12C-Mutant Lung Cancer?
Key Takeaways Regulatory Milestone Positions Lilly in the KRAS Race The U.S. FDA has granted Breakthrough Therapy designation…
Is Novartis’ $5.2B siRNA Expansion with Argo Biopharma the Next Big Move in Cardiovascular?
Key Takeaways Expanding RNAi Leadership in Cardiovascular and Metabolic Diseases Novartis is reinforcing its strategic focus on cardiovascular…
Could Merck’s Oral PCSK9 Inhibitor Enlicitide Transform Cholesterol Management?
Key Takeaways Breakthrough in Cardiovascular Innovation Merck announced positive topline Phase 3 results for enlicitide decanoate, its investigational…
Is Lilly’s “TuneLab” the Breakthrough AI Collaboration Model Biotech Startups Have Been Waiting For?
Key Highlights A bold move: Lilly democratizes AI for biotechEli Lilly has launched TuneLab, a novel AI platform…
Can Gilead’s Twice-Yearly Yeytuo® (Lenacapavir) Redefine HIV Prevention Across Europe With Zero Infections in Phase 3 Trials?
Key Insights: A Historic European Approval That Expands Prevention Choices The European Commission granted marketing authorization for Gilead’s…
